GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in…
GlaxoSmithKline plc announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell…
Read More...
Read More...